Cambrex closes on $425M deal for dosage-form CDMO Halo Pharma

Halo Pharma CDMO plant in Montreal, Canada
Halo Pharma operates two manufacturing plants in New Jersey and Quebec. (Halo Pharma)

New Jersey-based Cambrex closed on its $425 million acquisition of dosage-form CDMO Halo Pharma and the two manufacturing plants picked up in the deal.

Cambrex announced the acquisition of Halo from SK Capital, which has a number of CDMO holdings, in July.

“The acquisition is well-aligned with our commitment to providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers and the combines business creates a leading small molecule CDMO with both API and finished dosage development and manufacturing capabilities,” Steve Klosk, president and chief executive of Cambrex, said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Halo operates manufacturing sites in Whippany, New Jersey, and Montreal, comprising a total of 430,000 square feet of plant space. Its 450-person workforce will join Cambrex’s 1,200 employees across the U.S. and Europe.

SK Capital has been in the midst of a lot of consolidation in the CDMO market. Last year, Perrigo sold off its active pharmaceutical business to the investment group for $110 million.

Suggested Articles

Mylan is recalling a chemo drug and Hospira a commonly used solution because potentially dangerous particulate has been discovered in vials.

Lilly plans a $91 million plant expansion in Indianapolis, and a $7 million tax abatement tied to the project has generated some debate.

Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.